Suppr超能文献

膜联蛋白5作为蛋白激酶C介导的膜联蛋白1磷酸化的潜在调节因子。与人类内皮细胞膜联蛋白分布的定量数据相比的体外抑制作用。

Annexin 5 as a potential regulator of annexin 1 phosphorylation by protein kinase C. In vitro inhibition compared with quantitative data on annexin distribution in human endothelial cells.

作者信息

Raynal P, Hullin F, Ragab-Thomas J M, Fauvel J, Chap H

机构信息

INSERM Unité 326, Phospholipides Membranaires, Signalisation Cellulaire et Lipoprotéines, Hôpital Purpan, Toulouse, France.

出版信息

Biochem J. 1993 Jun 15;292 ( Pt 3)(Pt 3):759-65. doi: 10.1042/bj2920759.

Abstract

In vitro phosphorylation of annexin 1 by purified rat brain protein kinase C (PKC) has been studied in the presence of annexin 5, which is not a substrate for PKC. Annexin 5 promoted a dose-dependent inhibition of annexin 1 phosphorylation, which could be overcome by increasing the concentration of phosphatidylserine (PtdSer). In addition, a close relationship was found between the amount of PtdSer uncovered by annexin 5 and the residual phosphorylation of annexin 1. These data fit with the 'surface depletion model' explaining the antiphospholipase activity of annexins. In order to check the possibility that the in vitro effect of annexin 5 could be of some physiological relevance, annexins 1, 2, and 5, as well as the light chain of calpactin 1 (p11), have been quantified in human endothelial cells by measuring the radioactivity bound to the proteins after Western blotting with specific antibodies and 125I-labelled secondary antibody. Our data indicate that annexins 1 and 5, PKC and PtdSer are present in human endothelial cells in relative amounts very similar to those used in vitro under conditions permitting the detection of the inhibitory effect of annexin 5. Since annexin 1 remained refractory to PKC-dependent phosphorylation in intact cells, we suggest that annexin 5 might exert its inhibitory effect towards PKC in vivo, provided that its binding to phospholipids can occur at physiological (micromolar) concentrations of Ca2+. This was previously shown to occur in vitro using phosphatidylethanolamine/phosphatidic acid vesicles [Blackwood and Ernst (1990) Biochem. J. 266, 195-200]. Using identical assay conditions, which also allowed expression of PKC activity, annexin 5 again inhibited annexin 1 phosphorylation without interfering with PKC autophosphorylation. These data suggest that annexins 1 and 5 might interact with each other on the lipid surface, resulting in a specific inhibition of annexin 1 phosphorylation by PKC. Whether a similar mechanism also occurs in vivo remains to be determined.

摘要

在存在膜联蛋白5(它不是蛋白激酶C(PKC)的底物)的情况下,研究了纯化的大鼠脑蛋白激酶C对膜联蛋白1的体外磷酸化作用。膜联蛋白5促进了对膜联蛋白1磷酸化的剂量依赖性抑制,增加磷脂酰丝氨酸(PtdSer)的浓度可克服这种抑制。此外,发现膜联蛋白5暴露的PtdSer量与膜联蛋白1的残余磷酸化之间存在密切关系。这些数据符合解释膜联蛋白抗磷脂酶活性的“表面消耗模型”。为了检验膜联蛋白5的体外效应可能具有某些生理相关性的可能性,通过用特异性抗体和125I标记的二抗进行蛋白质印迹后测量与蛋白质结合的放射性,对人内皮细胞中的膜联蛋白1、2和5以及钙结合蛋白1轻链(p11)进行了定量。我们的数据表明,在允许检测膜联蛋白5抑制作用的条件下,膜联蛋白1和5、PKC和PtdSer在人内皮细胞中的相对含量与体外使用的非常相似。由于在完整细胞中膜联蛋白1对PKC依赖性磷酸化仍具有抗性,我们认为膜联蛋白5可能在体内对PKC发挥其抑制作用,前提是其与磷脂的结合能够在生理(微摩尔)浓度的Ca2+下发生。先前已证明在体外使用磷脂酰乙醇胺/磷脂酸囊泡时会发生这种情况[Blackwood和Ernst(1990年)《生物化学杂志》266,195 - 200]。使用相同的测定条件(该条件也允许PKC活性的表达),膜联蛋白5再次抑制膜联蛋白1的磷酸化,而不干扰PKC的自身磷酸化。这些数据表明,膜联蛋白1和5可能在脂质表面相互作用,导致PKC对膜联蛋白1磷酸化的特异性抑制。类似的机制在体内是否也会发生还有待确定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09b0/1134178/884b0120d4b5/biochemj00109-0148-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验